安徽阜阳那个医院皮肤科比较好阜阳市治皮肤好的医院,阜阳哪里有专业的皮肤医院,阜阳座疮医院哪家好,阜阳哪家医院看扁平疣啊,治疗荨麻诊阜阳哪家医院好点,阜阳治疗一次湿疹费用,在阜阳治疙瘩需要花多少钱啊

LOS ANGELES, June 5 (Xinhua) -- A latest study has found no evidence that screening for ovarian cancer may reduce the risk of dying from the disease, it was reported on Sunday.Screening, however, does increase the likelihood of unnecessary invasive procedures, according to researchers at the University of Utah.The researchers presented their findings at an on-going meeting of the American Society of Clinical Oncology in Chicago, The Los Angeles Times said.Researchers studied 78,216 women, ages 55 to 74, who participated in the National Cancer Institute's Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Half of the women received the usual care from their OB-gyns, and half received a CA 125 screening every year for six years and an ultrasound every year for four years. They were then followed for a maximum of 12 years.The researchers observed 212 ovarian cancers in the screened group and 176 in the normal care group. There were 118 ovarian cancer deaths in the screened group and 100 in the normal care group. The differences were not statistically significant. Overall, there were 2,924 deaths from all causes in the screened group and 2,914 in the normal care group.But the researchers also observed that 3,285 women had false- positive diagnoses from the screening. Among those, 1,080 underwent surgery that included an oophorectomy (surgical removal of one or both ovaries). Fifteen percent of those who had surgery developed major complications as a result. Overall, 1,771 women in the screened group (7.7 percent) had an oophorectomy, compared with 1,304 in the normal care group (5.8 percent)."We conclude that annual screening for ovarian cancer ... does not reduce disease-specific mortality in women at average risk for ovarian cancer but does increase invasive medical procedures and associated harms," the researchers said in the study.New data presented at the meeting also showed that the widely used cancer drug Avastin can improve treatment of ovarian cancer, The Times said.About 21,880 American women are diagnosed with ovarian cancer each year and about 13,850 die from it, according to the American Cancer Society. Because it produces few symptoms, the disease is typically not diagnosed until it has become advanced and spread throughout the body. As a result, five-year survival is only about 30 percent, and the disease is one of the five most deadly cancers among women. Being able to detect the cancer at an earlier stage when it might be more curable could thus, theoretically, improve the survival rate.The tests most commonly used to detect ovarian cancer include a transvaginal ultrasound to look for tumor masses and a blood test that screens for increased levels of a tumor marker called CA 125.

CAIRO, July 4 (Xinhua) -- U.S. and Italian archeologists have discovered the oldest description about an Egyptian king (about 3, 200 BC) in Egypt's Aswan, Egyptian Antiquities Minister Zahi Hawass said on Monday.The engravings "traces back to when the Egyptian language firstly recorded in hieroglyphs and tells about a unique complete royal ceremony which was known in the ancient Egyptian era," said Hawass in a statement."The pharaoh appears to be wearing the Upper Egypt crown accompanied by (Horus apostles) at the royal court, " Hawass added.Horus is one of the oldest and most significant deities in the ancient Egyptian religion and was worshipped from at least the late Predynastic period through to Greco-Roman times."This discovery is considered a supplementary one at the site unearthed near in el-Hamdulab site in northern Aswan, archaeologists said.This is one of the latest discoveries in Egypt as the surrounding wall of Betah temple (1550 BC-1070 BC) and a gate traces back to Shabaka king era were unearthed on Saturday in Luxor.

BEIJING, Sept. 1 (Xinhua) -- Medicine prices at public clinics have been notably reduced thanks to a policy that promotes basic medicine, an office of the State Council said Thursday.Current price levels of basic medicine used by government-funded township hospitals and community clinics have been reduced an average of 25 percent from the levels two years ago when the policy started, according to a statement from the State Council office in charge of reforming the country's healthcare program.China has introduced a state list of basic medicine used by government-funded township hospitals and community clinics, which includes roughly 300 types of commonly-used Western and traditional Chinese medicine.Provincial governments will purchase basic medicine through public bidding and distribute them to local clinics.These clinics must not raise the prices of listed medicine and in return, the government will provide them with subsidies.The policy has been implemented at all township and community clinics in all the 31 provinces, municipalities and autonomous regions in the Chinese mainland, the statement said. 

SYDNEY, July 15 (Xinhua) -- The world's first drug to increase life expectancy of people with advanced melanoma has been approved for use in Australia, local media reported on Friday.The breakthrough drug Yervoy got approval from the Therapeutics Good Association (TGA) on Friday amid hopes it could add two years to the life of people with the most lethal form of skin cancer but for whom other treatments have failed, the Australian Associated Press (AAP) said.Clearance for the drug's use in Australia follows similar approvals by the U.S. health regulator in March.Yervoy works by attacking and destroying cancer cells.Patients are hooked up to an intravenous drip once every three weeks for a total of four doses.Professor Peter Hersey, consultant immunologist to the Melanoma Institute Australia, said no other drug had improved survival rates like Yervoy."Not all patients respond to it but those who do have a good chance of living longer than they would have otherwise," Hersey told AAP.While it may improve survival rates, Yervoy can produce side effects from diarrhea and vomiting to serious blood infections and kidney failure.The average survival time for people with advanced melanoma is just six months.A global study of 676 people with melanoma found that 45 percent of patients given Yervoy were still alive after one year, according to AAP.More than 20 percent lived at least two years, with a small number managing to survive for six years.A separate study, published in June, which showed similarly improved survival rates for patients with newly diagnosed advanced melanoma, has raised hopes that Yervoy could be made more widely available.Melanoma is the fourth most common cancer in Australia, with 10, 300 people diagnosed each year.

BEIJING, Sep. 1 (Xinhuanet) -- Apple lost another iPhone prototype at a Bay Area bar, according to media reports Thursday.It is reported that an Apple employee lost a prototype iPhone at San Francisco bar Cava 22 in late July, which is a tequila bar in the mission district.A joint investigation by Apple and San Francisco police searched a local house but could not find it, the reports added.It seems that Apple employees learned nothing from last year’s lost iPhone scandal. A prototype iPhone 4 was lost in a Redwood City bar last year.Apple has denied any knowledge of the incident, and San Francisco police stated that Apple did not file a police report for the lost merchandise.If the reports are true, it would be a big blow to Apple’s ego since the company takes pride in its secretive nature.